GlassScriptPhysician profile
Dayna Iverson
NPI 1326588344
$4,298.48
in general payments reported to CMS, 2019-2025
31 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,159 · 2022: $338 · 2023: $662 · 2024: $951 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,724 · Education: $78.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,723.95 |
| Education | $78.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $521.89 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $502.10 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $438.02 | 2021-2024 | Farxiga, Breztri |
| Corcept Therapeutics | $326.39 | 2024-2025 | Korlym |
| Abbvie INC. | $305.58 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $252.53 | 2021-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $205.68 | 2025 | Fanapt |
| Novo Nordisk INC | $204.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $202.55 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $169.19 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $141.37 | 2021-2025 | |
| Allergan, INC. | $133.09 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $128.71 | 2022-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $126.00 | 2022-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.51 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $80.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $73.88 | 2023-2025 | Cobenfy, Eliquis |
| Pfizer INC. | $70.87 | 2023-2024 | |
| Alkermes, INC. | $46.65 | 2025 | Lybalvi, Aristada |
| Amgen INC. | $34.65 | 2021 | |
| Neurocrine Biosciences, INC. | $33.40 | 2021-2024 | Ingrezza |
| Exact Sciences Corporation | $24.60 | 2025 | Cologuard Collection Kit |
| Merz North America, INC. | $23.55 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.85 | 2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $17.18 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.18 | 2021 | |
| Genentech USA, INC. | $16.52 | 2021 | |
| Hologic Sales and Service, LLC | $16.41 | 2021 | |
| Scpharmaceuticals INC. | $15.24 | 2023 | |
| Avanir Pharmaceuticals, INC. | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayna Iverson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.